Affiliations 

  • 1 Center for Pregnant Women with Diabetes, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  • 2 Masjid Tanah Health Clinic, Malacca, Malaysia
  • 3 Department of Endocrinology-Diabetes Center, Alexandra Hospital, Athens, Greece
  • 4 Department of Internal Medicine and Diabetology, Medical University of Łódź, Łódź, Poland
  • 5 Department of Internal Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands
  • 6 Department of Endocrinology, Centro Hospitalar e Universitário do Porto, Porto, Portugal
  • 7 Department of Medicine, Galway Diabetes Research Centre, National University of Ireland Galway, Galway, Ireland
  • 8 Novo Nordisk A/S, Søborg, Denmark
  • 9 Endodiabesidad: Clínica Durán & Asociados, Seville, Spain
  • 10 Department of Diabetology, Metabolic Diseases and Nutrition, University Hospital of Toulouse, University of Toulouse, Toulouse, France
  • 11 Department of Obstetrics and Gynecology, Clinical Hospital Center Zagreb, Zagreb, Croatia
  • 12 Centre for Diabetes and Nutrition Ludwigshafen, Ludwigshafen, Germany
  • 13 Metabolic Unit, Royal Victoria Hospital, Belfast, UK
J Matern Fetal Neonatal Med, 2022 Dec;35(25):7992-8000.
PMID: 34182866 DOI: 10.1080/14767058.2021.1940132

Abstract

AIMS: To examine clinical parameters, glycemic control, folic acid supplementation, and the presence of other chronic diseases during early pregnancy in the EVOLVE study population (women with pre-existing diabetes treated with injectable glucose-lowering drugs).

METHODS: Cross-sectional baseline evaluation of EVOLVE: an international, multicenter, non-interventional study investigating the safety of injectable glucose-lowering drugs in pregnant women with pre-existing type 1 (T1D) or type 2 diabetes (T2D). Data were collected at enrollment visit interviews before gestational week 16.

RESULTS: In total, 2383 women from 17 mainly European countries were enrolled in the study: 2122 with T1D and 261 with T2D; mean age was 31 and 33 years, and duration of diabetes was 15 and 6 years, respectively. For women with T1D or T2D, 63% and 75%, respectively, received basal and rapid-acting insulin, 36% and 3% rapid-acting insulin only, 0.7% and 14.0% basal insulin only, 0.2% and 5.4% premix insulin, 0.0% and 1.2% injectable glucagon-like peptide-1 receptor agonist treatment without insulin. In women with T1D or T2D, respectively, during early pregnancy, 59% and 62% had HbA1c <7.0% (53 mmol/mol); 16% and 36% reported not taking folic acid before or during early pregnancy. Overall, >40% of women had ≥1 chronic concomitant condition (predominantly thyroid disease or hypertension). Retinopathy was the most commonly reported diabetic complication. The most commonly reported previous pregnancy complication was miscarriage.

CONCLUSIONS: Baseline data from this large multinational population of women with pre-existing diabetes indicate that sub-optimal glycemic control, poor pregnancy planning, and chronic concomitant conditions were common in early pregnancy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications